Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SCope-D1: Subcutaneous Durvalumab in Lung Cancer
NCT04870112Phase 1Terminated
- Sponsor
- AstraZeneca
- Start
- Jun 2021
- Primary completion
- Aug 2023
- Modality
- Antibody Conjugates, Engineered Antibody Formats, PD-1/PD-L1 Inhibitors
- Countries
- 4
01
Overview
Phase 1, open-label trial of durvalumab in non-small cell lung cancer (NSCLC) and small cell lung cancer (SCLC) (2 arms), sponsored by AstraZeneca. Primary endpoints: Observed serum concentration (trough) at 16 months, Number of patients with injection site reactions and immune-mediated reactions at 16 months and 1 more. Started Jun 2021; status: terminated.
02
Drugs
durvalumab
03
Conditions
non-small cell lung cancer (NSCLC)small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT04870112.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04870112.